State health technology assessment under the abbreviated procedure

15.03.2021 Updated 01.10.2026 27141 views

Date:: 19.08.2026
INN:: 9-valent human papillomavirus vaccine (recombinant, adsorbed)
Claimed indication for medical use:: For active immunization of persons aged 9 years and older to prevent the following diseases caused by HPV: precancerous conditions and cancer of the cervix, vulva, vagina and anal canal caused by the HPV types included in the vaccine
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: human papillomavirus 9-valent vaccine (recombinant, adsorbed) dated 18.09.2026 (697 KB) (Downloaded: 01.10.2026 07:14:27)

Date:: 19.08.2026
INN:: Emicizumab
Claimed indication for medical use:: For routine prophylaxis to reduce the frequency of bleeding episodes in children from birth with hemophilia A (congenital factor VIII deficiency) with inhibitors to factor VIII
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure emicizumab of 18.09.2026 (805 KB) (Uploaded: 01.10.2026 07:14:28)

Date:: 19.08.2026
INN:: Emicizumab
Claimed indication for medical use:: For routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A (congenital deficiency of coagulation factor VIII) with inhibitors to factor VIII
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure emicizumab of 18.09.2026 (639 KB) (Uploaded: 01.10.2026 07:14:30)

Date:: 19.08.2026
INN:: Galsulfase
Claimed indication for medical use:: Treatment of patients with mucopolysaccharidosis type VI
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure galsulfase of 18.09.2026 (471 KB) (Uploaded: 01.10.2026 07:14:32)

Date:: 19.08.2026
INN:: Elosulfase alfa
Claimed indication for medical use:: Treatment of patients with mucopolysaccharidosis type IVA
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: elosulfase alfa of 18.09.2026 (497 KB) (Downloaded: 01.10.2026 07:14:33)

Date:: 06.05.2025
INN:: Agalsidase beta
Claimed indication for medical use:: Treatment of patients with Fabry disease
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: agalsidase beta of 04.08.2025 (561 KB) (Downloaded: 07.08.2025 14:55:34)

Date:: 06.05.2025
INN:: Elosulfase alfa
Claimed indication for medical use:: Treatment of patients with mucopolysaccharidosis type IVA
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: elosulfase alfa of 16.07.2025 (666 KB) (Downloaded: 21.07.2025 13:50:40)

Date:: 06.05.2025
INN:: Galsulfase
Claimed indication for medical use:: Treatment of patients with mucopolysaccharidosis type VI
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure galsulfase of 09.07.2025 (528 KB) (Uploaded: 18.07.2025 12:45:52)

Date:: 06.05.2025
INN:: Taliglucerase alfa
Claimed indication for medical use:: Treatment of patients with Gaucher disease type 1
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure taliglucerase alfa dated 30.06.2025 (710 KB) (Uploaded: 18.07.2025 12:45:56)

Date:: 06.05.2025
INN:: Laronidase
Claimed indication for medical use:: Treatment of patients with mucopolysaccharidosis type I
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure laronidase of 16.07.2025 (728 KB) (Uploaded: 21.07.2025 13:50:39)

Date:: 06.05.2025
INN:: Risdiplam
Claimed indication for medical use:: Treatment of spinal muscular atrophy in patients aged from
2 months
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: risdiplam of 04.08.2025 (611 KB) (Downloaded: 07.08.2025 14:55:35)

Date:: 06.05.2025
INN:: Alglucosidase alfa
Claimed indication for medical use:: Treatment of patients with Pompe disease
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure alglucosidase alfa dated 09.07.2025 (729 KB) (Uploaded: 18.07.2025 12:45:50)

Date:: 06.05.2025
INN:: Imiglucerase
Claimed indication for medical use:: Treatment of patients with Gaucher disease type 1
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure imiglucerase of 30.06.2025 (762 KB) (Uploaded: 18.07.2025 12:45:54)

Date:: 06.05.2025
INN:: Anti-inhibitor coagulant complex
Claimed indication for medical use:: Treatment of patients with the inhibitor form of hemophilia type
A or B
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: anti-inhibitor coagulant complex of 20.06.2025 (832 KB) (Uploaded: 18.07.2025 12:45:51)

Date:: 06.05.2025
INN:: Idursulfase
Claimed indication for medical use:: Treatment of patients with mucopolysaccharidosis type II
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure idursulfase of 20.06.2025 (518 KB) (Uploaded: 18.07.2025 12:45:53)

Date:: 06.05.2025
INN:: Human C1-esterase inhibitor
Claimed indication for medical use:: Treatment and prevention of attacks of angioedema
in adults and children with hereditary angioedema
Conclusion:: Conclusion of the authorized health technology assessment body under the abbreviated procedure, human C1 esterase inhibitor, dated 30.06.2025 (746 KB) (Downloaded: 18.07.2025 12:45:55)

Date:: 06.05.2025
INN:: Velaglucerase alfa
Claimed indication for medical use:: Treatment of patients with Gaucher disease type 1
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure velaglucerase alfa dated 30.06.2025 (743 KB) (Uploaded: 18.07.2025 12:45:51)

Date:: 11.12.2024
INN:: Human papillomavirus vaccine (types 6, 11, 16, 18), quadrivalent
Claimed indication for medical use:: Use in girls and women aged 9 to 45 years
for the prevention of diseases caused by HPV 6,
11, 16, 18 types, including cancer of the cervix, vulva,
vagina and anal canal; precancerous and
dysplastic conditions; genital warts; infections
caused by human papillomavirus.
Conclusion:: Conclusion<br /> of the authorized health technology assessment body under the abbreviated procedure: human papillomavirus vaccine (types 6, 11, 16, 18), quadrivalent, recombinant, dated 03.01.2025 (544 KB) (Uploaded: 06.01.2025 15:12:22)

Date:: 26.07.2024
INN:: Emicizumab / Emicizumab
Claimed indication for medical use:: For routine prophylaxis to prevent or
reduce the frequency of bleeding episodes in children from
birth with hemophilia A (congenital
factor VIII deficiency) with or without
inhibitors to factor VIII
Conclusion:: Conclusion of the authorized state HTA body under the abbreviated procedure: emicizumab of 22.08.24 (565 KB) (Uploaded: 02.09.2024 13:54:33)

Date:: 02.05.2024
INN:: Fibrinogen, human / Fibrinogen, human
Claimed indication for medical use:: Treatment of bleeding and perioperative prophylaxis in patients with congenital hypofibrinogenemia or afibrinogenemia with a tendency to bleeding
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: human fibrinogen dated 26.06.2024 (827 KB) (Uploaded: 28.06.2024 08:27:31)

Date:: 09.02.2023
INN:: Antithymocyte globulin (equine)
Claimed indication for medical use:: Treatment of patients with aplastic anemia
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: anti-thymocyte globulin (equine) of 17.07.23 (408 KB) (Uploaded: 18.07.2023 10:36:16)

Date:: 11.11.2022
INN:: Everolimus
Claimed indication for medical use:: Prophylaxis of graft rejection in adult patients with low to moderate immunological risk after allogeneic kidney transplantation.
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: everolimus (678 KB) (Uploaded: 16.05.2023 06:25:20)

Date:: 11.11.2022
INN:: Valganciclovir
Claimed indication for medical use:: Prevention of CMV infection in CMV-negative patients who have undergone transplantation of parenchymal organs from CMV-positive donors.
Conclusion:: Conclusion of the state health technology assessment under the abbreviated procedure, valganciclovir, dated 08.05.2023 (737 KB) (Downloaded: 11.05.2023 11:14:38)

Date:: 02.11.2022
INN:: Etelcalcetide
Claimed indication for medical use:: Treatment of secondary hyperparathyroidism in patients with chronic renal failure who are on hemodialysis
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: etelcalcetide (643 KB) (Downloaded: 13.01.2023 07:20:49)

Date:: 16.09.2022
INN:: Cefepime/Amikacin
Claimed indication for medical use:: Treatment of respiratory tract infections
Conclusion:: In accordance with the MoH letter of 17.03.2023 No. 24-04/6833/2-23, the Ministry of Health of Ukraine considers further health technology assessment of the specified medicinal product under the abbreviated procedure
inexpedient.

Date:: 16.09.2022
INN:: Ceftriaxone/Sulbactam
Claimed indication for medical use:: Treatment of respiratory tract infections
Conclusion:: In accordance with the MoH letter of 17.03.2023 No. 24-04/6833/2-23, the Ministry of Health of Ukraine considers further health technology assessment of the specified medicinal product under the abbreviated procedure
inexpedient.

Date:: 16.09.2022
INN:: Cefepime/Sulbactam
Claimed indication for medical use:: Treatment of respiratory tract infections
Conclusion:: In accordance with the MoH letter of 17.03.2023 No. 24-04/6833/2-23, the Ministry of Health of Ukraine considers further health technology assessment of the specified medicinal product under the abbreviated procedure
inexpedient.

Date:: 16.09.2022
INN:: Sunitinib
Claimed indication for medical use:: Advanced renal cell carcinoma (RCC)
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: sunitinib (756 KB) (Uploaded: 28.10.2022 12:45:37)

Date:: 08.09.2022
INN:: Eltrombopag
Claimed indication for medical use:: Treatment of patients with severe aplastic anemia (SAA) who have not received prior immunosuppressive therapy or responded poorly to prior treatment and are not suitable for hematopoietic stem cell transplantation
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: eltrombopag (628 KB) (Downloaded: 31.10.2022 16:13:02)

Date:: 05.09.2022
INN:: Pemetrexed
Claimed indication for medical use:: In combination with cisplatin, first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: pemetrexed (637 KB) (Downloaded: 26.10.2022 07:48:20)

Date:: 05.09.2022
INN:: Gefitinib
Claimed indication for medical use:: Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations (epidermal growth factor receptor tyrosine kinase
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: gefitinib (472 KB) (Uploaded: 26.10.2022 07:49:21)

Date:: 05.09.2022
INN:: Ibandronic acid
Claimed indication for medical use:: Prevention of skeletal-related events (pathological fractures, bone lesions requiring radiotherapy or surgical treatment) in patients with breast cancer with metastatic bone involvement
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: ibandronic acid (627 KB) (Downloaded: 31.10.2022 16:12:02)

Date:: 23.08.2022
INN:: Lenalidomide
Claimed indication for medical use:: Multiple myeloma
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: lenalidomide (418 KB) (Downloaded: 21.10.2022 11:59:41)

Date:: 23.08.2022
INN:: Azacitidine
Claimed indication for medical use:: Myelodysplastic syndrome (MDS) of intermediate-2 and high risk, according to the International Prognostic Scoring System (IPSS)
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: azacitidine (554 KB) (Uploaded: 28.10.2022 06:54:30)

Date:: 23.08.2022
INN:: Abiraterone
Claimed indication for medical use:: Metastatic castration-resistant prostate cancer
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: abiraterone (475 KB) (Downloaded: 31.10.2022 16:10:44)

Date:: 16.08.2022
INN:: Pomalidomide
Claimed indication for medical use:: For treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have previously received at least two courses of treatment with lenalidomide and bortezomib and who show disease progression on the last therapy
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: pomalidomide (716 KB) (Downloaded: 26.10.2022 07:50:59)

Date:: 16.08.2022
INN:: Everolimus
Claimed indication for medical use:: Treatment, in combination with exemestane, of advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women without rapidly progressing visceral disease, if prior therapy with nonsteroidal aromatase inhibitors resulted in recurrence or progression
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: everolimus (638 KB) (Uploaded: 28.10.2022 12:44:35)

Date:: 16.08.2022
INN:: Dasatinib
Claimed indication for medical use:: Treatment of adult patients with chronic myeloid leukemia in the chronic phase, accelerated phase, or blast phase with resistance or intolerance to prior treatment that included imatinib mesylate
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: dasatinib (305 KB) (Uploaded: 29.09.2022 06:19:31)

Date:: 16.08.2022
INN:: Fulvestrant
Claimed indication for medical use:
Conclusion:: . Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: fulvestrant (488 KB) (Downloaded: 31.10.2022 16:13:54)

Date:: 28.07.2022
INN:: Darbepoetin alfa
Claimed indication for medical use:: Treatment of symptomatic anemia associated with chronic renal failure in dialysis patients
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: darbepoetin alfa (286 KB) (Downloaded: 07.09.2022 09:36:14)

Date:: 09.06.2022 / 01.09.2022
INN:: Laronidase
Claimed indication for medical use:: Treatment of patients with mucopolysaccharidosis type I
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: laronidase (523 KB) (Uploaded: 28.07.2022 10:11:55)
Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: laronidase of 01.09.2022 (496 KB) (Uploaded: 06.09.2022 07:06:57)

Date:: 09.06.2022 / 01.09.2022
INN:: Idursulfase
Claimed indication for medical use:: Treatment of patients with mucopolysaccharidosis type II
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: idursulfase (484 KB) (Downloaded: 28.07.2022 10:12:21)
Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: idursulfase of 25.07.2022 (477 KB) (Uploaded: 06.09.2022 07:08:28)

Date:: 09.06.2022 / 01.09.2022
INN:: Galsulfase
Claimed indication for medical use:: Treatment of patients with mucopolysaccharidosis type VI
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: galsulfase (454 KB) (Downloaded: 28.07.2022 10:12:39)
Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: galsulfase of 25.07.2022 (431 KB) (Uploaded: 06.09.2022 07:09:48)

Date:: 09.06.2022 / 01.09.2022
INN:: Elosulfase alfa
Claimed indication for medical use:: Treatment of patients with mucopolysaccharidosis type IVA
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: elosulfase alfa (514 KB) (Downloaded: 28.07.2022 10:13:01)
Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: elosulfase alfa of 25.07.2022 (510 KB) (Downloaded: 06.09.2022 07:10:59)

Date:: 09.06.2022 / 01.09.2022
INN:: Velaglucerase alfa
Claimed indication for medical use:: Treatment of patients with Gaucher disease type 1
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: velaglucerase alfa (479 KB) (Uploaded: 14.07.2022 11:16:54)
Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: velaglucerase alfa dated 13.07.2022 (530 KB) (Uploaded: 06.09.2022 07:11:56)

Date:: 09.06.2022 / 01.09.2022
INN:: Taliglucerase alfa
Claimed indication for medical use:: Treatment of patients with Gaucher disease type 1
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: taliglucerase alfa (431 KB) (Uploaded: 14.07.2022 11:17:29)
Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: taliglucerase alfa dated 13.07.2022 (463 KB) (Uploaded: 06.09.2022 07:12:54)

Date:: 09.06.2022
INN:: Agalsidase alfa
Claimed indication for medical use:: Treatment of patients with Fabry disease
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: agalsidase alfa (621 KB) (Downloaded: 29.09.2022 06:22:03)

Date:: 09.06.2022
INN:: Agalsidase beta
Claimed indication for medical use:: Treatment of patients with Fabry disease
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: agalsidase beta (562 KB) (Downloaded: 29.09.2022 06:22:53)

Date:: 09.06.2022
INN:: Alglucosidase alfa
Claimed indication for medical use:: Treatment of patients with Pompe disease
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure: alglucosidase alfa (670 KB) (Uploaded: 29.09.2022 06:23:51)

Date:: 09.06.2022
INN:: Anti-inhibitor coagulant complex
Claimed indication for medical use:: Treatment of patients with inhibitor-positive hemophilia type A or B
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: anti-inhibitor coagulant complex (468 KB) (Uploaded: 06.09.2022 07:15:02)

Date:: 09.06.2022
INN:: Human C1- esterase inhibitor
Claimed indication for medical use:: Treatment and prevention of angioedema attacks in adults and children with hereditary angioedema
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: human C1-esterase inhibitor (584 KB) (Downloaded: 29.09.2022 06:25:00)

Date:: 17.04.2022
INN:: Electrolytes/Electrolytes
Claimed indication for medical use:: Treatment of adult patients with sepsis and/or septic shock combined with lactic acidosis
Conclusion:: Opinion of the authorized body for state health technology assessment under the abridged procedure: electrolytes (sodium chloride + potassium chloride + calcium chloride dihydrate + magnesium chloride hexahydrate + sodium acetate trihydrate + L-malic acid) (532 KB) (Downloaded: 06.06.2022 06:53:27)

Date:: 17.02.2022
INN:: Dapagliflozin / Dapagliflozin
Claimed indication for medical use:: Use of dapagliflozin in addition to metformin (i.e., in combination with metformin), as a representative of standard therapy, for the treatment of adult patients with type 2 diabetes mellitus and a risk of cardiovascular disease, for glycemic control and reduction of the risk of cardiovascular complications.
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: dapagliflozin (563 KB) (Downloaded: 20.06.2022 11:31:25)

Date:: 17.02.2022 / 01.09.2022
INN:: Imiglucerase / Imiglucerase
Claimed indication for medical use:: Treatment of Gaucher disease type 1
Conclusion:: Opinion of the authorized body for state health technology assessment under the abbreviated procedure (621 KB) (Uploaded: 25.05.2022 10:38:09)
Conclusion of the authorized body for state health technology assessment under the abbreviated procedure of 23.05.2022 (568 KB) (Uploaded: 06.09.2022 07:16:25)

Date:: 31.12.2021
INN:: Albumin
Claimed indication for medical use:: Treatment of patients with decompensated liver cirrhosis (including that caused by viral hepatitis) to maintain circulating blood volume and, if necessary, the use of colloids
Conclusion:: Conclusion of the authorized body for state health technology assessment under the abbreviated procedure: albumin. (616 KB) (Uploaded: 25.03.2022 07:02:17)

Date:: 29.12.2021
INN:: Human normal immunoglobulin for intravenous administration
Claimed indication for medical use:: Replacement immunotherapy in the treatment of primary and secondary immunodeficiency conditions and related diseases: – secondary antibody deficiency syndrome, namely in chronic leukemia (chronic lymphocytic leukemia).
Conclusion:: Conclusion of the state HTA under the abbreviated procedure: human normal immunoglobulin for intravenous administration 10% of 28.01.2022 (715 KB) (Downloaded: 31.01.2022 13:02:30)

Date:: 05.11.2021
INN:: L-alanine; L-arginine; L-aspartic acid; L-cysteine; L-glutamic acid; glycine; L-histidine; L-isoleucine; L-leucine; L-lysine monohydrate (equivalent to lysine); L-methionine; L-ornithine hydrochloride (equivalent to ornithine); L-phenylalanine; L-proline; L-serine; taurine; L-threonine; L-tryptophan; L-tyrosine; L-valine; potassium acetate; calcium chloride, dihydrate; magnesium acetate, tetrahydrate; sodium glycerophosphate, hydrate; glucose, monohydrate (equivalent to anhydrous glucose); refined olive oil and refined soybean oil.
Claimed indication for medical use:: Parenteral nutrition of premature newborns with very low (≤1500 g) and extremely low birth weight (≤1000 g)
Conclusion:: Conclusion of the authorized body for state HTA under the abbreviated procedure: Solution for parenteral nutrition comprising an amino acid solution, a lipid emulsion and a glucose solution

Date:: 14.09.2021 / 01.09.2022
INN:: Emicizumab / Emicizumab
Claimed indication for medical use:: Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A (congenital factor VIII deficiency) with the development of inhibitors to factor VIII.
Conclusion:: Conclusion of the authorized body on state health technology assessment under the abbreviated procedure (emicizumab)

Conclusion of the authorized body on state health technology assessment under the abbreviated procedure (emicizumab) of 06.10.2021 (482 KB) (Uploaded: 06.09.2022 07:18:06)

Date:

13.08.2021 / 02.11.2021

INN:

Dimethyl fumarate / Dimethylfumarate

Claimed indication for medical use:

Treatment of adult patients with relapsing-remitting multiple sclerosis

Conclusion:

Conclusion of the state HTA under the abbreviated procedure for Dimethyl fumarate of 09.09.2021.

Conclusion of the state HTA under the abbreviated procedure
Dimethyl fumarate of 26.11.2021

Date:: 19.03.2021
INN:: Amino acids / Amino acids
Claimed indication for medical use:: Partial parenteral nutrition of premature infants, newborns and young children (for the medical services package “Medical care for newborns in complex neonatal cases”)
Conclusion:: Conclusion of the state HTA under the abbreviated procedure Amino acids

Date:: 19.03.2021
INN:: Fat emulsions / Fat emulsions
Claimed indication for medical use:: For parenteral nutrition of low-birth-weight newborns (for the medical services package "Medical care for newborns in complex neonatal cases")
Conclusion:: Conclusion of the state HTA under the abbreviated procedure Fat emulsions

Date:: 19.03.2021
INN:: Alteplase / Alteplase
Claimed indication for medical use:: Thrombolytic treatment of acute ischemic stroke (for the medical services package “Medical care for acute cerebral stroke”)
Conclusion:: Conclusion of the state HTA under the abbreviated procedure Alteplase

Date:: 19.03.2021
INN:: Fondaparinux sodium / Fondaparinux
Claimed indication for medical use:: Treatment of unstable angina or non-ST-segment elevation myocardial infarction in patients for whom urgent (<120 min) invasive intervention (percutaneous coronary intervention – PCI) is not indicated (for the medical services package “Medical care for acute myocardial infarction”)
Conclusion:: Conclusion of the state HTA under the abbreviated procedure Fondaparinux sodium

Date:: 19.03.2021
INN:: Norepinephrine tartrate / Norepinephrine
Claimed indication for medical use:: Urgent (immediate) restoration of arterial pressure in cases of acute hypotension (for the medical services package "Medical care for acute cerebral stroke")
Conclusion:: Conclusion of the state HTA under the abbreviated procedure for Noradrenaline tartrate

Date:: 19.03.2021
INN:: Methoxy polyethylene glycol-epoetin beta / Methoxy polyethylene glycol-epoetin
Claimed indication for medical use:: Treatment of symptomatic anemia associated with chronic kidney disease (for the medical services package "Treatment of patients by hemodialysis in outpatient settings"
Conclusion:: State HTA conclusion under the abbreviated procedure: Methoxy polyethylene glycol-epoetin beta

Date:: 19.03.2021
INN:: Colecalciferol / Colecalciferol
Claimed indication for medical use:: Prevention of rickets in premature newborns, prevention of rickets (for the medical services package "Medical Care for Newborns in Complex Neonatal Cases"
Conclusion:: Conclusion of the state HTA under the abbreviated procedure Cholecalciferol